Brief: U.S. FDA Grants RMAT Designation To Galapagos' GLPG5101
06/08/2025 06:32
Aug 6 (Reuters) - Galapagos NV GLPG.AS: GALAPAGOS NV - ANNOUNCES U.S. FDA REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION GRANTED TO GLPG5101 FOR TREATMENT OF RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA Source text: ID:nGNE3dtjXM Further company coverage: GLPG.AS (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 587 785 110;))
Recent news on Lakefront Biotherapeutics NV
See all newsBrief: Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
Brief: Lakefront Receives Transparency Notification From Bank Of America
Belgium's Galapagos Q1 revenue falls 91% but returns to profit
Brief: Galapagos, Gilead Enter Binding Agreement On Ouro Medicines Acquisition
Brief: Galapagos Announces Nomination Of Gino Santini To Its Board Of Directors